Oseltamivir-zanamivir combination therapy is not superior to zanamivir monotherapy in mice infected with influenza A(H3N2) and A(H1N1)pdm09 viruses

Antiviral Research

Volumn 105, Issue 1, 2014, Pages 54-58

  Pizzorno, Andrés ^a,b   Abed, Yacine ^a,b   Rhéaume, Chantal ^a,b   Boivin, Guy ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

Combination; Influenza; Neuraminidase inhibitors; Oseltamivir; Resistance; Zanamivir

Indexed keywords

LANTHANUM; OSELTAMIVIR; ZANAMIVIR; ANTIVIRUS AGENT; 4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; SODIUM CHLORIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL RESISTANCE; ARTICLE; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; FEMALE; INFLUENZA A (H1N1); INFLUENZA A (H3N2); INFLUENZA A (H3N2)PDM09; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H1N1PDM09; INFLUENZA VIRUS A H3N2; INOCULATION; MONOTHERAPY; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT RESPONSE; VIRUS TITRATION; WEIGHT REDUCTION; WILD TYPE; ANIMAL; BODY WEIGHT; C57BL MOUSE; COMPARATIVE STUDY; DISEASE MODEL; DRUG COMBINATION; ISOLATION AND PURIFICATION; LUNG; ORTHOMYXOVIRIDAE INFECTIONS; PROCEDURES; SURVIVAL; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD; ANTIVIRAL SUSCEPTIBILITY; ANTIVIRAL THERAPY; CONTROLLED STUDY; IC 50;

ANIMALS; ANTIVIRAL AGENTS; BODY WEIGHT; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; LUNG; MICE, INBRED C57BL; ORTHOMYXOVIRIDAE INFECTIONS; OSELTAMIVIR; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VIRAL LOAD; ZANAMIVIR;

EID: 84896516581     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2014.02.017     Document Type: Article

References (11)

1. F. Carrat, X. Duval, F. Tubach, A. Mosnier, S. Van der Werf, A. Tibi, T. Blanchon, C. Leport, A. Flahault, and F. Mentre Effect of oseltamivir, zanamivir or oseltamivir-zanamivir combination treatments on transmission of influenza in households Antiviral Ther. 17 6 2012 1085 1090
2. L.M. Cass, C. Efthymiopoulos, and A. Bye Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers Clin. Pharmacokinet. 36 Suppl 1 1999 1 11 (Pubitemid 29322452)
3. X. Duval, S. van der Werf, T. Blanchon, A. Mosnier, M. Bouscambert-Duchamp, A. Tibi, V. Enouf, C. Charlois-Ou, C. Vincent, L. Andreoletti, F. Tubach, B. Lina, F. Mentre, and C. Leport Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial PLoS Med. 7 11 2010 e1000362
4. V. Escuret, C. Cornu, F. Boutitie, V. Enouf, A. Mosnier, M. Bouscambert-Duchamp, S. Gaillard, X. Duval, T. Blanchon, C. Leport, F. Gueyffier, S. Van Der Werf, and B. Lina Oseltamivir-zanamivir bitherapy compared to oseltamivir monotherapy in the treatment of pandemic 2009 influenza A(H1N1) virus infections Antiviral Res. 96 2 2012 130 137
5. S. Kubo, T. Tomozawa, M. Kakuta, A. Tokumitsu, and M. Yamashita Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration Antimicrob. Agents Chemother. 54 3 2010 1256 1264
6. A. Moscona Neuraminidase inhibitors for influenza N. Engl. J. Med. 353 13 2005 1363 1373 (Pubitemid 41362704)
7. J.T. Nguyen, J.D. Hoopes, M.H. Le, D.F. Smee, A.K. Patick, D.J. Faix, P.J. Blair, M.D. de Jong, M.N. Prichard, and G.T. Went Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro PLoS One 5 2 2010 e9332
8. A. Pizzorno, X. Bouhy, Y. Abed, and G. Boivin Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitors J. Infect. Dis. 203 1 2011 25 31
9. M. Potier, L. Mameli, M. Belisle, L. Dallaire, and S.B. Melancon Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-alpha-D- N-acetylneuraminate) substrate Anal. Biochem. 94 2 1979 287 296 (Pubitemid 9173017)
10. S. Pukrittayakamee, P. Jittamala, K. Stepniewska, N. Lindegardh, S. Chueasuwanchai, W. Leowattana, A. Phakdeeraj, S. Permpunpanich, W. Hanpithakpong, W. Pan-Ngum, C. Fukuda, S. Panapipat, P. Singhasivanon, N.J. White, and N.P. Day An open-label crossover study to evaluate potential pharmacokinetic interactions between oral oseltamivir and intravenous zanamivir in healthy Thai adults Antimicrob. Agents Chemother. 55 9 2011 4050 5057
11. D.F. Smee, B.L. Hurst, M.H. Wong, E.B. Tarbet, Y.S. Babu, K. Klumpp, and J.D. Morrey Combinations of oseltamivir and peramivir for the treatment of influenza A (H1N1) virus infections in cell culture and in mice Antiviral Res. 88 1 2010 38 44